US Stem Cell (USRM) Ratios
US Stem Cell Ratios
USRM's free cash flow for Q4 2022 was $-43.06K. For the 2022 fiscal year, USRM's free cash flow was increased by $0.00 and operating cash flow was $-43.06K. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.25 |
| Quick Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 |
| Solvency Ratio | -0.19 | -0.09 | -0.25 | -0.38 | -0.22 |
| Operating Cash Flow Ratio | -0.02 | -0.09 | -0.04 | -0.14 | 0.10 |
| Short-Term Operating Cash Flow Coverage | -0.04 | -0.15 | -0.07 | -0.22 | 0.25 |
| Net Current Asset Value | $ -14.75M | $ -12.77M | $ -11.58M | $ -9.50M | $ -7.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 131.50 | 157.19 | 84.91 | 68.80 | 2.78 |
| Debt-to-Equity Ratio | -0.61 | -0.63 | -0.65 | -0.65 | -0.73 |
| Debt-to-Capital Ratio | -1.54 | -1.69 | -1.83 | -1.87 | -2.76 |
| Long-Term Debt-to-Capital Ratio | -0.05 | -0.06 | -0.07 | -0.09 | -0.59 |
| Financial Leverage Ratio | -0.00 | -0.00 | -0.01 | -0.01 | -0.26 |
| Debt Service Coverage Ratio | -0.24 | -0.02 | -0.33 | -0.41 | -0.13 |
| Interest Coverage Ratio | -2.49 | -2.14 | -4.91 | -3.48 | -0.76 |
| Debt to Market Cap | 3.15 | 2.90 | 1.43 | 4.44 | 0.86 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Net Debt to EBITDA | -4.12 | -52.68 | -3.11 | -2.37 | -7.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 71.03% | 74.08% | 76.86% | 56.54% | 68.50% |
| EBIT Margin | -2642.28% | -1139.37% | -866.92% | -92.91% | -10.68% |
| EBITDA Margin | -2642.28% | -75.42% | -866.24% | -85.01% | -7.59% |
| Operating Profit Margin | -2096.90% | -1063.94% | -866.24% | -111.22% | -16.38% |
| Pretax Profit Margin | -3483.21% | -1637.58% | -1043.17% | -124.84% | -32.24% |
| Net Profit Margin | -3483.21% | -1637.58% | -1043.17% | -124.84% | -32.24% |
| Continuous Operations Profit Margin | -3483.21% | -1637.58% | -1043.17% | -124.84% | -32.24% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 166.11% | 153.92% | 120.43% | 112.25% | 196.78% |
| Return on Assets (ROA) | -4200.45% | -6446.04% | -3278.99% | -4268.93% | -118.89% |
| Return on Equity (ROE) | 19.38% | 25.75% | 24.96% | 40.46% | 31.39% |
| Return on Capital Employed (ROCE) | 12.28% | 17.82% | 22.31% | 39.45% | 26.78% |
| Return on Invested Capital (ROIC) | 29.95% | 45.48% | 59.44% | 104.13% | 66.78% |
| Return on Tangible Assets | -4200.45% | -6446.04% | -3278.99% | -4268.93% | -118.89% |
| Earnings Yield | -100.65% | -118.90% | -55.19% | -275.30% | -36.93% |
| Efficiency Ratios | |||||
| Receivables Turnover | 18.94 | 165.50 | 5.12 | 63.73 | 371.55 |
| Payables Turnover | 0.01 | 0.04 | 0.05 | 1.12 | 1.78 |
| Inventory Turnover | 24.25 | 132.39 | 11.83 | 164.93 | 22.64 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 27.62 |
| Asset Turnover | 1.21 | 3.94 | 3.14 | 34.20 | 3.69 |
| Working Capital Turnover Ratio | -0.01 | -0.02 | -0.03 | -0.47 | -1.37 |
| Cash Conversion Cycle | -24915.10 | -9629.78 | -7195.93 | -316.81 | -187.44 |
| Days of Sales Outstanding | 19.27 | 2.21 | 71.35 | 5.73 | 0.98 |
| Days of Inventory Outstanding | 15.05 | 2.76 | 30.84 | 2.21 | 16.12 |
| Days of Payables Outstanding | 24949.42 | 9634.74 | 7298.12 | 324.75 | 204.54 |
| Operating Cycle | 34.32 | 4.96 | 102.19 | 7.94 | 17.10 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -119721.50 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -119721.50 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.03 | -0.13 | -0.06 | -0.20 | 0.12 |
| Operating Cash Flow to Sales Ratio | -3.72 | -5.27 | -1.73 | -0.39 | 0.09 |
| Free Cash Flow Yield | -10.74% | -38.27% | -9.14% | -86.93% | 10.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.99 | -0.84 | -1.81 | -0.36 | -2.71 |
| Price-to-Sales (P/S) Ratio | 34.61 | 13.77 | 18.90 | 0.45 | 0.87 |
| Price-to-Book (P/B) Ratio | -0.19 | -0.22 | -0.45 | -0.15 | -0.85 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.31 | -2.61 | -10.94 | -1.15 | 9.71 |
| Price-to-Operating Cash Flow Ratio | -9.31 | -2.61 | -10.94 | -1.15 | 9.71 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | -0.14 | 0.05 | -0.01 | 0.06 |
| Enterprise Value Multiple | -5.43 | -70.94 | -5.29 | -2.90 | -18.77 |
| Enterprise Value | 11.78M | 10.74M | 12.70M | 7.57M | 9.54M |
| EV to EBITDA | -5.43 | -70.94 | -5.29 | -2.90 | -18.77 |
| EV to Sales | 143.59 | 53.51 | 45.85 | 2.47 | 1.42 |
| EV to Free Cash Flow | -38.65 | -10.15 | -26.53 | -6.25 | 15.84 |
| EV to Operating Cash Flow | -38.65 | -10.15 | -26.53 | -6.25 | 15.84 |
| Tangible Book Value Per Share | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Shareholders’ Equity Per Share | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Net Income Per Share | -0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.32 | 1.44 | 1.20 | 1.34 | 3.02 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 4.68 | 2.77 | 2.53 | 0.27 | 0.18 |
| Income Quality | 0.11 | 0.32 | 0.17 | 0.32 | -0.28 |
Currency in USD
